Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 14 peer-reviewed journal articles Updated
Neurology

Standard of Care and Targeted Therapies

At a Glance

Treatment for Neurocutaneous Melanocytosis (NCM) focuses on managing neurological symptoms with anti-seizure medications and shunts, alongside emerging targeted therapies. MEK inhibitors like trametinib are increasingly used to target the underlying NRAS mutation and help stabilize the disease.

Managing symptomatic Neurocutaneous Melanocytosis (NCM) requires a specialized, multidisciplinary approach. Because the condition is rare and complex, your care team will focus on two main goals: relieving immediate physical pressure in the brain and using new “targeted” medicines to address the underlying genetic cause of the disease [1][2].

Standard Management of Symptoms

For many years, treatment for NCM focused solely on managing the physical complications caused by melanin deposits:

  • Hydrocephalus and Pressure: If fluid builds up in the brain, a neurosurgeon may place a ventriculoperitoneal (VP) shunt [3]. This tube safely drains excess fluid into the abdomen, where it can be reabsorbed [3][4].
  • Seizure Control: Seizures are typically managed with standard antiepileptic medications, such as levetiracetam [2][5].
  • Surgical Decompression: In some cases, a surgeon may perform a procedure to remove a specific mass of pigment cells or create more space for the brain to stabilize neurological symptoms [1][6].

The Shift Away from Traditional Oncology

Historically, doctors tried to treat malignant CNS melanoma (cancerous NCM) with traditional chemotherapy (like temozolomide) or radiation [1][7]. Unfortunately, research has shown that these traditional methods have limited success in NCM, often failing to significantly change the course of the disease [7][8].

Emerging Hope: Targeted MEK Inhibitors

The most significant breakthrough in NCM care is the use of targeted therapies [9]. Because NCM is caused by a “stuck switch” in the NRAS pathway, doctors are now using drugs called MEK inhibitors (such as trametinib) to try and flip that switch back to “off” [10][11].

  • How They Work: Unlike chemotherapy, which attacks all fast-growing cells, MEK inhibitors specifically target the signals telling the mutated cells to grow [11].
  • Results: Small studies and individual cases have shown that these drugs can stabilize neurological symptoms, prevent further decline, and in some instances, even reduce the size of melanin deposits in the brain [2][12].
  • Long-Term Management, Not a Cure: It is important to understand that MEK inhibitors are typically chronic, long-term management therapies. They do not “cure” the condition, but they can control it [2].
  • Monitoring Side Effects: These are powerful medications that require close monitoring. Common side effects include skin rashes, diarrhea, and rare but important effects on the heart or eyes (retinopathy) [13][14].

While these treatments are often considered “emerging” or “off-label,” they represent a major shift toward more precise, effective care for NCM [2][9]. Your care team will help you weigh the potential benefits against side effects to find the best path forward.

Common questions in this guide

How are seizures and brain fluid buildup managed in NCM?
Seizures are typically controlled with anti-seizure medications like levetiracetam. If fluid builds up in the brain and causes pressure (hydrocephalus), a neurosurgeon may place a VP shunt to safely drain the excess fluid into the abdomen.
Do traditional cancer treatments work for neurocutaneous melanocytosis?
Historically, doctors tried traditional chemotherapy and radiation for cancerous NCM, but research shows these methods have limited success and often fail to significantly change the course of the disease.
What are MEK inhibitors and how do they treat NCM?
MEK inhibitors, such as trametinib, are targeted therapies that block the specific growth signals caused by the NRAS mutation in NCM. While not a cure, they can stabilize neurological symptoms and sometimes reduce the size of melanin deposits in the brain.
What baseline tests are needed before starting a drug like trametinib?
Because MEK inhibitors are powerful medications with specific side effects, your care team will likely perform baseline evaluations of your heart, eyes, and skin before starting treatment so they can safely monitor for any changes.
How will my doctor know if the targeted therapy is working?
Your care team will measure the success of targeted therapies through a combination of regular follow-up MRI scans to check the size of melanin deposits and careful monitoring to see if your neurological symptoms are improving or remaining stable.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Has the biopsy or sample been tested for a somatic NRAS mutation (such as codon 61)?
  2. 2.If we start a targeted therapy like trametinib, what specific 'baseline' tests (heart, eye, skin) do we need to do first?
  3. 3.How will we measure if a targeted therapy is actually working—will we use follow-up MRIs or symptom monitoring?
  4. 4.Are there any clinical trials or expanded access programs specifically for NRAS-mutated NCM that we should consider?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (14)
  1. 1

    Neurosurgical management of patients with neurocutaneous melanosis: a systematic review.

    Rahman RK, Majmundar N, Ghani H, et al.

    Neurosurgical focus 2022; (52(5)):E8 doi:10.3171/2022.2.FOCUS21791.

    PMID: 35535823
  2. 2

    Symptomatic neurocutaneous melanosis: mild clinical onset in a teenager.

    Vanood A, Lee YA, Leleszi E, Krishnan A

    BMJ case reports 2020; (13(11)) doi:10.1136/bcr-2020-235772.

    PMID: 33257354
  3. 3

    Shunt Surgery for Neurocutaneous Melanosis with Hydrocephalus: Case Report and Review of the Literature.

    Omar AT, Bagnas MAC, Del Rosario-Blasco KAR, et al.

    World neurosurgery 2018; (120()):583-589.e3 doi:10.1016/j.wneu.2018.09.002.

    PMID: 30205217
  4. 4

    Neurocutaneous Melanocytosis-Associated Hydrocephalus: The Memorial Sloan Kettering Experience from 2001 to 2022.

    Rodriguez S, DeIeso-Frechette F, Umeasor C, et al.

    Pediatric blood & cancer 2025; (72(1)):e31434 doi:10.1002/pbc.31434.

    PMID: 39502030
  5. 5

    Diagnostic and therapeutic approach for neurocutaneous melanosis in a young adult.

    Alessandro L, Blaquier JB, Bártoli J, Diez B

    Neurologia 2019; (34(5)):336-338 doi:10.1016/j.nrl.2016.09.008.

    PMID: 27939117
  6. 6

    Primary Malignant Meningeal Melanoma Complicated by Cerebral Venous Sinus Thrombosis: An Illustrative Case With a Systematic Review of the Literature.

    Mann JA, Bhatt D, Tso MK

    Cureus 2024; (16(8)):e66710 doi:10.7759/cureus.66710.

    PMID: 39262554
  7. 7

    Neurocutaneous Melanosis with Leptomeningeal Melanoma Involving Supratentorium and Infratentorium.

    Thomas S, Patel B, Varghese SS, Backianathan S

    Cureus 2018; (10(9)):e3275 doi:10.7759/cureus.3275.

    PMID: 30443446
  8. 8

    Primary Central Nervous System Malignant Melanoma in Children: A Case Series and Review of the Literature.

    Choi DK, Pillay-Smiley N, Marzec S, et al.

    Journal of pediatric hematology/oncology 2018; (40(8)):616-619 doi:10.1097/MPH.0000000000001092.

    PMID: 29401100
  9. 9

    Melanoma in congenital melanocytic naevi.

    Kinsler VA, O'Hare P, Bulstrode N, et al.

    The British journal of dermatology 2017; (176(5)):1131-1143 doi:10.1111/bjd.15301.

    PMID: 28078671
  10. 10

    Congenital Melanocytic Nevus Syndrome: A Case Series.

    Recio A, Sánchez-Moya AI, Félix V, Campos Y

    Actas dermo-sifiliograficas 2017; (108(9)):e57-e62 doi:10.1016/j.ad.2016.07.025.

    PMID: 28110826
  11. 11

    MEK inhibition appears to improve symptom control in primary NRAS-driven CNS melanoma in children.

    Kinsler VA, O'Hare P, Jacques T, et al.

    British journal of cancer 2017; (116(8)):990-993 doi:10.1038/bjc.2017.49.

    PMID: 28253523
  12. 12

    Targeted therapy for infants with diencephalic syndrome: A case report and review of management strategies.

    Wagner LM, Myseros JS, Lukins DE, et al.

    Pediatric blood & cancer 2018; (65(5)):e26917 doi:10.1002/pbc.26917.

    PMID: 29369501
  13. 13

    Trametinib-associated Hyponatremia in a Child With Low-grade Glioma is Not Seen Following Treatment With Alternative MEK Inhibitor.

    Lazow MA, Lawson SA, Salloum R, et al.

    Journal of pediatric hematology/oncology 2021; (43(4)):e550-e553 doi:10.1097/MPH.0000000000001859.

    PMID: 32520842
  14. 14

    Risk factors for MEK-associated retinopathy in patients with advanced melanoma treated with combination BRAF and MEK inhibitor therapy.

    Booth AEC, Hopkins AM, Rowland A, et al.

    Therapeutic advances in medical oncology 2020; (12()):1758835920944359 doi:10.1177/1758835920944359.

    PMID: 32821295

This information about NCM treatments and targeted therapies is for educational purposes only. Always consult your neuro-oncologist or neurologist before starting or changing any medications or treatment plans.

Get notified when new evidence is published on Neurocutaneous melanocytosis.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.